A frailty index predicts post-liver transplant morbidity and mortality in HIV-positive patients

Giovanni Guaraldi, Giovanni Dolci, Stefano Zona, Giuseppe Tarantino, Valentina Serra, Roberto Ballarin, Erica Franceschini, Mauro Codeluppi, Thomas D. Brothers, Cristina Mussini, Fabrizio Benedetto

Résultat de recherche: Articleexamen par les pairs

16 Citations (Scopus)

Résumé

Background: We hypothesized that frailty acts as a measure of health outcomes in the context of LT. The aim of this study was to explore frailty index across LT, as a measure of morbidity and mortality. This was a retrospective observational study including all consecutive 47 HIV+patients who received LT in Modena, Italy from 2003 to June 2015. Methods: frailty index (FI) was constructed from 30 health variables. It was used both as a continuous score and as a categorical variable, defining 'most frail' a FI > 0.45. FI change across transplant (deltaFI, ΔFI) was calculated as the difference between year 1 FI (FI-Y1) and pre-transplant FI (FI-t0). The outcomes measures were mortality and "otpimal LT" (defined as being alive without multi-morbidity). Results: Median value of FI-t0 was 0.48 (IQR 0.42-0.52), FI-Y1 was 0.31 (IQR 0.26-0.41). At year five mortality rate was 45%, "optimal transplant" rate at year 1 was 38%. All the patients who died in the post-LT were most frail in the pre-LT. ΔFI was a predictor of mortality after correction for age and MELD (HR = 1.10, p = 0.006) and was inversely associated with optimal transplant after correction for age (HR = 1.04, p = 0.01). Conclusions: We validated FI as a valuable health measure in HIV transplant. In particular, we found a relevant correlation between FI strata at baseline and mortality and a statistically significant correlation between, ΔFI and survival rate.

Langue d'origineEnglish
Numéro d'article37
JournalAIDS Research and Therapy
Volume14
Numéro de publication1
DOI
Statut de publicationPublished - août 5 2017

Note bibliographique

Funding Information:
GG received research grants from Gilead Sciences, ViiV healthcare and Merck. He received honoraria as speaker and/or advisor from Gilead Sciences, GlaxoSmithKline, Merck, Jansen, BMS. GD received research grants from Gilead Sciences. All other authors declare that they have no competing interests.

Publisher Copyright:
© 2017 The Author(s).

ASJC Scopus Subject Areas

  • Molecular Medicine
  • Virology
  • Pharmacology (medical)

Empreinte numérique

Plonger dans les sujets de recherche 'A frailty index predicts post-liver transplant morbidity and mortality in HIV-positive patients'. Ensemble, ils forment une empreinte numérique unique.

Citer